Author Archives: uaemevidence

Considerations for a demonstration pooled fund for R&D based on CEWG recommendations

Pneumonia vaccine is not cost effective in middle income countries

Sofosbuvir+Ledipasvir FDC generic market prices in India 26th of April 2016

FDA has low efficacy threshold for approving cancer medicines

How the MDGs gave up on measuring access to medicines

Drug price increases are common in the USA

Falsified drugs are less of a problem (anti-malarials) than drug quality, which is a regulatory issue

Evergreening is common

The purported ‘innovation dip’ is an artefact of the time periods previously studied. Reports of declining innovation need to be considered in the context of their timescale and perspective.

Only 36% of people with cancer in India receive any form of treatment

Dealing with intellectual property issues linked to affordability and access to medicines, included in the WHO Essential Medicines List (EML).

A liberal economists perspective on why patents may not promote innovation.

Hedge-fund style Pharmaceutical strategies impact patients the most, but have less impact on health systems and insurance companies than do smaller price increases on widely used drugs.

Tool to assess disparity between resources dedicated to a disease and its relative burden on society

IP on basic research reduces subsequent scientific research and product development

Impact on poverty in India by household expenditure on health care

Pharma lobbying expenditures

Examples of enormous price raises of old drugs

Excessive profit margins by Big Pharma rebutted by R&D costs, long-term healthcare savings, and short window to make profit.

Summary of clinical trial transparency in the EU / EU Ombudsman rules clinical trials not trade secrets

Pharma profit margins are very high

New (much better) evidence that pharma marketing spend > R&D spend

IFPMA’s incoming president quoted by Lilly saying there is no evidence that patents affect A2M

Cases of UK government using compulsory licenses

Sofosbuvir reference collection

Original de-linkage proposal

Prize fund for HIV (S.1138)

MSF 3P (Push, pull, pool) Project for TB

Marketing is the enemy of Innovation (Applbaum)

Generic production results in price drop of >80% for widely used drugs

Recent example of catastrophic licensing of university-invented drug

India slams U.S. on University partnerships with industry

US public research (NIH) translates into higher health impact than private research

Cochrane Collab founder Iain Chalmers challenges ABPI’s claim that 90% drugs come from industry

Econ review supporting feasibility of NTD R&D using push and pull mechanisms

Possible to produce Hep-C drugs for far lower, affordable price

UN Special Rapporteur’s mission to GSK (responsibility of Pharma to uphold right to health)

MSF’s experience in openness

CPTech’s (KEI) summary of pharma-favoured academics

COUNTERING: “only 1-4% of essential medicines are patented”

Patent protection leads to decreased quality of diagnostics (in gene research)

Patent protection does not contribute to innovation (in gene research)

Half of all health R&D funding is from public/not-for-profit sources (2005, data from OECD + others)

Only small proportion of patent portfolio applied for before product launch, patents continue steadily after launch

Pharma takes out as many patents as they can

Only 2% of patent apps refused by EPO 2000-7

4% of drugs registered 2000-11 for NTDs; 4 NCEs

R&D cost estimates are impossible to verify due to secrecy